Platelet transfusion containing ABO-incompatible plasma and hepatic veno-occlusive disease after hematopoietic transplantation in young children

Transplantation

Volumn 80, Issue 3, 2005, Pages 314-319

  Lapierre, Valérie ^a,b,c   Mahé, Cédric ^a   Aupérin, Anne ^a   Stambouli, Férial ^a   Oubouzar, Nadia ^a   Tramalloni, Dominique ^a   Benhamou, Ellen ^a   Tiberghien, Pierre ^b   Hartmann, Olivier ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

ABO incompatibility; Autologous hematopoietic stem cell transplantation; Children; Hepatic veno occlusive disease; Platelet transfusion

Indexed keywords

BLOOD GROUP A ANTIGEN; BLOOD GROUP B ANTIGEN; BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN; O ANTIGEN; THIOTEPA; THROMBOCYTE CONCENTRATE;

ADOLESCENT; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD GROUP ABO INCOMPATIBILITY; BRAIN TUMOR; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; DRUG MEGADOSE; EVALUATION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; INFANT; LIVER VEIN OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEPHROBLASTOMA; PLASMA; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE TRANSFUSION; TIME; VASCULAR ENDOTHELIUM;

ABO BLOOD-GROUP SYSTEM; ADOLESCENT; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; BUSULFAN; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; LIVER DISEASES; MALE; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; PLATELET TRANSFUSION; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 23744458801     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000167758.63247.f4     Document Type: Article

References (32)

1. Matthay KK, Villabianca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165.
2. Bearman SI, Anderson GL, Mori M, et al. Veno-occlusive disease of the liver: development of a model for predicting fatal outcome after bone marrow transplantation. J Clin Oncol 1993; 11: 1729.
3. Carreras E, Bertz H, Arcese W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation Chronic Leukemia Working Group. Blood 1998; 92: 3599.
4. Ozkaynak MF, Weinberg K, Kohn D, et al. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome. Bone Marrow Transplant 1991; 7: 467.
5. Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135.
6. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome. Semin Liver Dis 2002; 22: 27.
7. Holgersson J, Breimer ME, Samuelsson BE. Basic biochemistry of cell surface carbohydrates and aspects of the tissue distribution of histo-blood group ABH and related glycosphingolipids. APMIS 1992; 27(Suppl.): 18.
8. Heal JM, Rowe JM, Blumberg N. ABO and platelet transfusion revisited. Ann Hematol 1993; 66: 309.
9. Janeway CA, Travers P. Immune responses in the absence of infection. In: Janeway, CA, Travers P, eds. Immunobiology. The immune system in health and disease. 1st ed. New York, Current Biology Ltd./Garland Publishing Inc, 1994.
10. Heal JM, Rowe JM, McMican A, et al. The role of ABO matching in platelet transfusion. Eur J Haematol 1993; 50: 110.
11. Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Results of a randomized trial. Transfusion 1989; 29: 384.
12. Styler MJ, Crilley P, Biggs J, et al. Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. Bone Marrow Transplant 1996; 18: 171.
13. Vassal G, Koscielny S, Challine D, et al. Busulfan disposition and hepatic veno-occlusive in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37: 247.
14. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789.
15. Coze C, Hartmann O, Michon J, et al. NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol 1997; 15: 3433.
16. Doireau V, Grill J, Zerah M, et al. Chemotherapy for unresectable and recurrent intramedullary glial tumours in children. Brain Tumours Subcommittee of the French Society of Paediatric Oncology (SFOP). Br J Cancer 1999; 8: 835.
17. Lassau N, Leclere J, Auperin A, et al. Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients. Radiology 1997; 204: 545.
18. Nelson W. Theory and application for hazard plotting for censored failure time data. Technometrics 1972; 14: 945.
19. Valteau-Couanet D, Benhamou E, Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000; 25: 937.
20. Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746 50.
21. Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic venoocclusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2004; published online.
22. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786.
23. Horn B, Reiss U, Matthay K, et al. Veno-occlusive disease of the liver in children with solid tumors undergoing autologous hematopoietic progenitor cell transplantation: a high incidence in patients with neuroblastoma. Bone Marrow Transplant 2002; 29: 409.
24. Römer J, Morgenthaler JJ, Scherz R, Skvaril F. Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang 1982; 42: 62.
25. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant Group. Ann Intern Med 1993; 118: 937
26. Klaesson S, Ringden O, Ljungman P, et al. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Transplantation 1995; 60: 1225.
27. Sullivan KM, Kansu E, Storer B, et al. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Biol Blood Marrow Transplant 1998; 4: 20.
28. Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? Ann Intern Med 2003; 139: 8.
29. Gugenheim J, Samuel D, Reynes M, Bismuth H. Liver transplantation across ABO blood group barriers. Lancet 1990; 336: 519.
30. Attal M, Huguet F, Rubie H, et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 1992; 79: 2834.
31. Essell JH, Schroeder MT, Harman GS, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975.
32. Ohashi K, Tanabe J, Watanabe R, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32.